Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Income from Continuing Operations (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Income from Continuing Operations for 7 consecutive years, with 14796000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 6.47% year-over-year to 14796000.0, compared with a TTM value of 77627000.0 through Dec 2025, down 14.3%, and an annual FY2025 reading of 77627000.0, down 14.3% over the prior year.
  • Income from Continuing Operations was 14796000.0 for Q4 2025 at aTYR PHARMA, up from 26745000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 7202000.0 in Q1 2021 and bottomed at 26745000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 14043950.0, with a median of 13525000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 487.41% in 2021, then grew 7.99% in 2022.
  • Year by year, Income from Continuing Operations stood at 8640000.0 in 2021, then grew by 7.99% to 7950000.0 in 2022, then tumbled by 100.74% to 15959000.0 in 2023, then rose by 0.87% to 15820000.0 in 2024, then rose by 6.47% to 14796000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ATYR at 14796000.0 in Q4 2025, 26745000.0 in Q3 2025, and 20313000.0 in Q2 2025.